Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use

Chevrier,Sandy; Chevrier,Sandy; Chevrier,Sandy; Brasselet,Astrid; Brasselet,Astrid; Brasselet,Astrid; Carnet,Marion; Carnet,Marion; Carnet,Marion; Chevriaux,Angélique; Chevriaux,Angélique; Chevriaux,Angélique; Gibeaud,Anne; Gibeaud,Anne; Gibeaud,Anne; Jourdain,Marine; Jourdain,Marine; Jourdain,Marine; Mananet,Hugo; Mananet,Hugo; Mananet,Hugo; Truntzer,Caroline; Truntzer,Caroline; Truntzer,Caroline; Beltjens,Françoise; Beltjens,Françoise; Beltjens,Françoise; Charon‑Barra,Céline; Charon‑Barra,Céline; Charon‑Barra,Céline; Arnould,Laurent; Arnould,Laurent; Arnould,Laurent; Albuisson,Juliette; Albuisson,Juliette; Albuisson,Juliette; Comte,Anthony; Comte,Anthony; Comte,Anthony; Derangère,Valentin; Derangère,Valentin; Derangère,Valentin; Goussot,Vincent; Goussot,Vincent; Goussot,Vincent; Boidot,Romain; Boidot,Romain; Boidot,Romain

doi:10.3892/ijmm.2022.5113

Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use

Authors:
- Sandy Chevrier
- Astrid Brasselet
- Marion Carnet
- Angélique Chevriaux
- Anne Gibeaud
- Marine Jourdain
- Hugo Mananet
- Caroline Truntzer
- Françoise Beltjens
- Céline Charon‑Barra
- Laurent Arnould
- Juliette Albuisson
- Anthony Comte
- Valentin Derangère
- Vincent Goussot
- Romain Boidot
View Affiliations

Affiliations: Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges‑François Leclerc Cancer Center‑UNICANCER, 21079 Dijon, France, Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumors, Georges‑François Leclerc Cancer Center‑UNICANCER, 21079 Dijon, France, Unit of Pathology, Department of Biology and Pathology of Tumors, Georges‑François Leclerc Cancer Center‑UNICANCER, 21079 Dijon, France
Published online on: March 3, 2022 https://doi.org/10.3892/ijmm.2022.5113
Article Number: 57
Copyright: © Chevrier et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular testing is extremely important in cancer care, starting as early as at diagnosis. In order to address the challenge of providing reliable results within the timeframe adapted to patient management and suitable to guide clinical decisions, a capture‑based next‑generation sequencing (NGS) panel focusing on ten genes known to harbor genetic variations which may be targeted by approved drugs in patients with cancer was designed and validated. Very favorable analytical performances were obtained for both solid and liquid biopsies. For solid biopsies, a low read depth (80X per nucleotide) led to the genotype detection accuracy of 100%. The read of raw data for liquid biopsies resulted in the 91.19% result concordance between paired solid and liquid samples. The present method met all the requirements for the ISO15189 certification. During our three‑year experience of routinely using this panel, almost 2,300 samples from lung and colorectal cancers, melanomas and gastrointestinal stromal tumors have been analyzed. It was found that our panel detected slightly more gain‑of‑function variants than described in the literature. Surprisingly, loss‑of‑function variants were also detected in certain of the analyzed genes. Finally, liquid biopsy data revealed statistically different mutated allele frequencies between tumor types, but also between mutated genes and variants themselves. In conclusion, the use of our capture‑based NGS panel is perfectly adapted to perform relevant molecular diagnosis in a time frame compatible with patient care.

View Figures

View References

1	Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D and Gray JW: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 89:5321–5325. 1992. View Article : Google Scholar : PubMed/NCBI
2	Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, et al: Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 3:111–116. 2008. View Article : Google Scholar : PubMed/NCBI
3	Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
4	Nguyen-Ngoc T, Bouchaab H, Adjei AA and Peters S: BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol. 10:1396–1403. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
6	Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA and Neal JW: ERBB2-Mutated metastatic non-small cell lung cancer: Response and resistance to targeted therapies. J Thorac Oncol. 12:833–842. 2017. View Article : Google Scholar : PubMed/NCBI
7	Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, et al: Sotorasib for lung cancers with KRAS G12C mutation. N Engl J Med. 384:2371–2381. 2021. View Article : Google Scholar : PubMed/NCBI
8	Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, et al: Capmatinib in MET Exon 14-Mutated or MET-Amplified non-small-cell lung cancer. N Engl J Med. 383:944–957. 2020. View Article : Google Scholar : PubMed/NCBI
9	Sanz-Garcia E, Argiles G, Elez E and Tabernero J: BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives. Ann Oncol. 28:2648–2657. 2017. View Article : Google Scholar : PubMed/NCBI
10	Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
11	Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
12	Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
13	Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, et al: KIT as a therapeutic target in metastatic melanoma. JAMA. 305:2327–2334. 2011. View Article : Google Scholar : PubMed/NCBI
14	Johnson DB and Puzanov I: Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol. 16:152015. View Article : Google Scholar : PubMed/NCBI
15	Lasota J and Miettinen M: KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 23:91–102. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar :
17	Li H: Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv 1303.3997v2. 2013.
18	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The genome analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
19	DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 43:491–498. 2011. View Article : Google Scholar : PubMed/NCBI
20	Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al: From FastQ data to high confidence variant calls: The genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 43:11 10 11–11 10 33. 2013.
21	Toolkit Picard: Broad Institute, GitHub Repository. 2019, https://broadinstitute.github.io/picard/.
22	Muller E, Goardon N, Brault B, Rousselin A, Paimparay G, Legros A, Fouillet R, Bruet O, Tranchant A, Domin F, et al: OutLyzer: Software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice. Oncotarget. 7:79485–79493. 2016. View Article : Google Scholar : PubMed/NCBI
23	Wang K, Li M and Hakonarson H: ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
24	Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6:80–92. 2012. View Article : Google Scholar
25	Andrews S: FastQC: A quality control tool for high thoughput sequence data. 2010, http://www.bioinformatics.babraham.ac.uk/projects/fastqc.
26	Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R: 1000 Genome Project Data Processing Subgroup: The sequence alignment/map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
27	Okonechnikov K, Conesa A and Garcia-Alcalde F: Qualimap 2: Advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 32:292–294. 2016.
28	Ewels P, Magnusson M, Lundin S and Kaller M: MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 32:3047–3048. 2016. View Article : Google Scholar : PubMed/NCBI
29	Boidot R, Végran F and Ghiringhelli F: Detection method of somatic genetic anomalies, combination of capture probes and kit of detection. EP3553182. Filed April 11, 2018 issued October 16, 2019.
30	Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV and Nikiforova MN: Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the association for molecular pathology and college of american pathologists. J Mol Diagn. 19:341–365. 2017. View Article : Google Scholar : PubMed/NCBI
31	Papadopoulou E, Tsoulos N, Tsantikidi K, Metaxa-Mariatou V, Stamou PE, Kladi-Skandali A, Kapeni E, Tsaousis G, Pentheroudakis G, Petrakis D, et al: Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS One. 14:e02268532019. View Article : Google Scholar : PubMed/NCBI
32	Esagian SM, Grigoriadou GI, Nikas IP, Boikou V, Sadow PM, Won JK and Economopoulos KP: Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: A comprehensive systematic review. J Cancer Res Clin Oncol. 146:2051–2066. 2020. View Article : Google Scholar : PubMed/NCBI
33	Garcia J, Kamps-Hughes N, Geiguer F, Couraud S, Sarver B, Payen L and Ionescu-Zanetti C: Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Sci Rep. 11:107612021. View Article : Google Scholar : PubMed/NCBI
34	Shen WD, Chen HL and Liu PF: EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR mono-clonal antibodies in metastatic colorectal cancer treatment: A meta-analysis. Chin J Cancer Res. 26:59–71. 2014.PubMed/NCBI
35	Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, et al: Amplification of Wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clin Cancer Res. 24:5963–5976. 2018. View Article : Google Scholar : PubMed/NCBI
36	Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, et al: EGFR amplification in metastatic colorectal cancer. J Natl Cancer Inst. 113:1561–1569. 2021. View Article : Google Scholar : PubMed/NCBI
37	Suryavanshi M, Shah A, Kumar D, Panigrahi MK, Metha A and Batra U: MET amplification and response to MET inhibitors in stage IV lung adenocarcinoma. Oncol Res Treat. 40:198–202. 2017. View Article : Google Scholar : PubMed/NCBI
38	Chen D, Zhang LQ, Huang JF, Liu K, Chuai ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q and Fu WL: BRAF mutations in patients with non-small cell lung cancer: A systematic review and meta-analysis. PLoS One. 9:e1013542014. View Article : Google Scholar : PubMed/NCBI
39	Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, et al: KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: Poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 7:397212017. View Article : Google Scholar : PubMed/NCBI
40	Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB and Ladanyi M: MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 21:1935–1943. 2015. View Article : Google Scholar :
41	Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, et al: Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 387:1415–1426. 2016. View Article : Google Scholar : PubMed/NCBI
42	Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 7:78985–78993. 2016. View Article : Google Scholar : PubMed/NCBI
43	Bellio H, Fumet JD and Ghiringhelli F: Targeting BRAF and RAS in colorectal cancer. Cancers (Basel). 13:22012021. View Article : Google Scholar
44	Chuang J, Wang C, Guo Y, Valenzuela V, Wu J and Fakih M: MAP2K1 mutations in advanced colorectal cancer predict poor response to anti-EGFR therapy and to vertical targeting of MAPK pathway. Clin Colorectal Cancer. 20:72–78. 2021. View Article : Google Scholar : PubMed/NCBI
45	Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, et al: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 124:1358–1373. 2018. View Article : Google Scholar : PubMed/NCBI
46	Gutierrez-Castaneda LD, Nova JA and Tovar-Parra JD: Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: A systemic review. Melanoma Res. 30:62–70. 2020. View Article : Google Scholar :
47	Mei L, Smith SC, Faber AC, Trent J, Grossman SR, Stratakis CA and Boikos SA: Gastrointestinal stromal tumors: The GIST of precision medicine. Trends Cancer. 4:74–91. 2018. View Article : Google Scholar : PubMed/NCBI
48	Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
49	Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I and Johnson FM: Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med. 4:136ra702012. View Article : Google Scholar : PubMed/NCBI
50	Robert NJ, Nwokeji ED, Espirito JL, Chen L, Karhade M, Evangelist MC, Spira AI, Neubauer MA, Bullock SA, Coleman RL, et al: Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J Clin Oncol. 39(Suppl 15)9004:2021. View Article : Google Scholar